References
- Scheindlin S . Our man in Dorpat: Richard Buchheim and the birth of pharmacology. Mol. Interv.10 (6), 331–335 (2010).
- Hubbard LS , HuberGL, MenziK. The Story of the Chemical Industry in Basle.Urs Graf Publishers, Olten and Lausanne, Switzerland (1959).
- Rolinson GN . Forty years of β–lactam research. J. Antimicrob. Chemother.41 (6), 589–603 (1998).
- Gant TW . Skills and training for the 21st century chemical toxicologist. Chem. Res. Toxicol.24 (7), 985–987 (2011).
- Alex AA , StorerRI. Drugs and their structural motifs. In:RSC Drug Discovery Series No. 1.SmithDA ( Ed.). Royal Society of Chemistry, Cambridge, UK, 1–60 (2010).
- North PC , OxfordAW, FenuikW, HumphreyPPA, ConnorHE. Migraine therapy – from serotonin to sumatriptan. In:Medicinal Chemistry Principles and Practice.KingFD ( Ed.). Royal Society of Chemistry, Cambridge, UK, 265–277 (1994).
- Humphrey PPA . The discovery of a new drug class for the acute treatment of migraine. Headache47 (Suppl. 1), S10–S19 (2007).
- White AW , GriffinRJ, GoldingBTet al. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase. J. Med. Chem.43 (22), 4084–4097 (2000).
- Ferraris DV . Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J. Med. Chem.53 (12), 4561–4584 (2010).
- Plummer R . Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside. Clin. Oncol.26 (5), 250–256 (2014).
- Bourzac K . Beating the big three. Nature507 (7490), S4–S7 (2014).